1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Clozapine belongs to the dibenzazepine class of psychotropics and it is marketed under the brand names Clozaril and Leponex by Novartis, and FazaClo (an ODT formulation) by Jazz Pharmaceuticals. The drug is unique in its receptor-binding profile: thanks to its receptor selectivity, Clozaril should be considered in patients who fail to respond to two consecutive antipsychotics (one of which should be atypical) and in patients who display persistent suicidality.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Clozaril including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Clozaril for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Clozaril performance
- Obtain sales forecast for Clozaril from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 11
3.2 Symptoms 12
4 Disease Management 13
4.1 Diagnosis 13
4.1.1 Subjective Assessments 14
4.1.2 Disease Subtypes 15
4.2 Treatment Overview 18
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 20
4.2.2 Maintenance Treatment of Schizophrenia 21
5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 23
6 Clozaril (clozapine) 25
6.1 Overview 25
6.2 Efficacy in Treatment-Resistant Schizophrenia 26
6.3 Safety 26
6.4 SWOT Analysis 26
6.5 Forecast 27
7 Appendix 28
7.1 Bibliography 28
7.2 Abbreviations 30
7.3 Methodology 31
7.4 Forecasting Methodology 31
7.4.1 Diagnosis and Treatment Rates 31
7.4.2 Adherence Rates 32
7.4.3 General Pricing Assumptions 32
7.4.4 Drug Assumptions 33
7.4.5 Generic Erosion 34
7.5 Key Opinion Leaders 35
7.6 About the Authors 36
7.6.1 Author 36
7.6.2 Reviewers 36
7.6.3 Global Head of Healthcare 37
7.7 About GlobalData 38
7.8 Disclaimer 38

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 12
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 15
Table 3: Development-Based Classification of Antipsychotic Drugs 18
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 19
Table 5: Guidelines for the Treatment of Schizophrenia 20
Table 6: Leading Branded Treatments for Schizophrenia, 2013 24
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 24
Table 8: Product Profile - Clozaril 25
Table 9: Clozaril SWOT Analysis, 2014 26
Table 10: Global Sales Forecast ($m) for Clozaril, 2012-2022 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.